LLY

916.49

-1.52%↓

JNJ

237.15

-0.37%↓

ABBV

208.28

-5.27%↓

NVS

149.76

-3.06%↓

AZN

188.42

-1.47%↓

LLY

916.49

-1.52%↓

JNJ

237.15

-0.37%↓

ABBV

208.28

-5.27%↓

NVS

149.76

-3.06%↓

AZN

188.42

-1.47%↓

LLY

916.49

-1.52%↓

JNJ

237.15

-0.37%↓

ABBV

208.28

-5.27%↓

NVS

149.76

-3.06%↓

AZN

188.42

-1.47%↓

LLY

916.49

-1.52%↓

JNJ

237.15

-0.37%↓

ABBV

208.28

-5.27%↓

NVS

149.76

-3.06%↓

AZN

188.42

-1.47%↓

LLY

916.49

-1.52%↓

JNJ

237.15

-0.37%↓

ABBV

208.28

-5.27%↓

NVS

149.76

-3.06%↓

AZN

188.42

-1.47%↓

Kodu・Aktsiate loetelu・Apellis Pharmaceuticals Inc

Apellis Pharmaceuticals Inc

Suletud

SektorTervishoid

17.95 -4.57

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

17.38

Max

18.81

Põhinäitajad
By Trading Economics
Sissetulek	-297M -81M
Müük	-259M 200M
P/E Sektori keskmine	104.556 57.833
Aktsiakasum	1.67
Kasumimarginaal	-40.687
Töötajad	733
EBITDA	-275M -47M

Soovitused
By TipRanks
Soovitused	Osta
12 kuu keskmine prognoos	+67.09% upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	6. mai 2026

Turustatistika
By TradingEconomics
Turukapital	-437M 2.4B
Eelmine avamishind	22.52
Eelmine sulgemishind	17.95

Apellis Pharmaceuticals Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

18. märts 2026, 22:51 UTC

Tulu

AIA Group Value of New Business Rose in 2025, Plans $1.7 Billion New Share Buyback

18. märts 2026, 21:40 UTC

Omandamised, ülevõtmised, äriostud

Constellation Energy to Sell Portfolio of Assets for $5 Billion to Satisfy Regulators

18. märts 2026, 20:31 UTC

Tulu

Micron 2Q Sales Nearly Triple Amid Tight Memory Supply

18. märts 2026, 23:49 UTC

Market Talk

Uudisväärsed sündmused

Nikkei May Fall on Renewed Concerns About Higher Energy Prices -- Market Talk

18. märts 2026, 23:31 UTC

Market Talk

Gold Rises on Likely Technical Recovery -- Market Talk

18. märts 2026, 22:49 UTC

Market Talk

New Zealand's Economic Recovery Has Yet to Find Footing -- Market Talk

18. märts 2026, 22:41 UTC

Market Talk

Woodside Energy Opts for 'Safe, Experienced' Choice as CEO -- Market Talk

18. märts 2026, 22:36 UTC

Tulu

AIA Group Value of New Business Rose in 2025, Plans $1.7B New Share Buyback

18. märts 2026, 22:24 UTC

Tulu

AIA Group Announces New Share Buyback of $1.7B >1299.HK

18. märts 2026, 22:23 UTC

Tulu

AIA Group 2025 Value of New Business Margin Was 58.5%, Up 3.6 Ppt on Year >1299.HK

18. märts 2026, 22:23 UTC

Tulu

AIA Group 2025 Value of New Business $5.52B Vs. $4.71B >1299.HK

18. märts 2026, 21:58 UTC

Tulu

Micron Sales Nearly Triple Amid Tight Memory Supply -- Update

18. märts 2026, 21:55 UTC

Market Talk

Tulu

Global Equities Roundup: Market Talk

18. märts 2026, 21:55 UTC

Market Talk

Tulu

Micron's Phone, PC Business Could Shrink Due to Memory Shortage -- Market Talk

18. märts 2026, 21:40 UTC

Market Talk

Fuel Price Rise Equates to 20 Bps Rate Hike on Australian Households -- Market Talk

18. märts 2026, 21:16 UTC

Market Talk

More Procter & Gamble Alumni Join Strobel at Coty -- Market Talk

18. märts 2026, 21:00 UTC

Uudisväärsed sündmused

Iran War Puts Pressure on Japan's Economy. Takaichi Is In a Bind. -- Barrons.com

18. märts 2026, 20:58 UTC

Tulu

Micron 2Q Gross Margin Nearly Doubled Due to Higher Pricing, CFO Says

18. märts 2026, 20:41 UTC

Tulu

Micron Reports Extraordinary Earnings. Its Growth Is Accelerating. -- Barrons.com

18. märts 2026, 20:29 UTC

Tulu

Micron Reports Extraordinary Earnings. Its Growth Is Accelerating. -- Barrons.com

18. märts 2026, 20:25 UTC

Tulu

Micron Reports Extraordinary Earnings. Its Growth Is Accelerating. -- Barrons.com

18. märts 2026, 20:17 UTC

Tulu

These Stocks Are Today's Movers: Micron, Swarmer, Lumentum, Trade Desk, Macy's, Williams-Sonoma, and More -- Barrons.com

18. märts 2026, 20:14 UTC

Market Talk

Airlines Can't Offset Higher Fuel Prices for Long -- Market Talk

18. märts 2026, 20:09 UTC

Tulu

Micron Reports Extraordinary Earnings. The Stock Is Up. -- Barrons.com

18. märts 2026, 20:07 UTC

Tulu

Micron Technology Raises Qtr Dividend to 15c Vs. 11.5c >MU

18. märts 2026, 20:06 UTC

Tulu

Micron Technology Board Has Approved 30% Increase in Qtrly Div >MU

18. märts 2026, 20:04 UTC

Tulu

Micron Technology 2Q Operating Cash Flow $11.9 B >MU

18. märts 2026, 20:04 UTC

Tulu

Micron Technology Sees 3Q Operating Expenses About $1.6 B >MU

18. märts 2026, 20:04 UTC

Tulu

Micron Technology Sees 3Q Gross Margin About 81% >MU

18. märts 2026, 20:03 UTC

Tulu

Micron Technology Sees 3Q Adj EPS $19.15 +/- 40c >MU

Võrdlus sarnastega

Hinnamuutus

Apellis Pharmaceuticals Inc Prognoos

Hinnasiht

By TipRanks

67.09% tõus

12 kuu keskmine prognoos

Keskmine 31.53 USD 67.09%

Kõrge 48 USD

Madal 18 USD

Põhineb 16 Wall Streeti analüütiku instrumendi Apellis Pharmaceuticals Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

16 ratings

Osta

Hoia

Müü

Põhineb 16 analüütiku instrumendi Apellis Pharmaceuticals Inc aktsia reitingul - viimase 3 kuu andmed.

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Apellis Pharmaceuticals Inc

Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA). The company also develops APL-3007, a small interfering RNA, or siRNA, which is in a Phase 1 clinical trial, as well as an oral complement inhibitor that is in preclinical development. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) for development and commercialization of pegcetacoplan; and a collaboration with Beam Therapeutics Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. The company was incorporated in 2009 and is based in Waltham, Massachusetts.